It remains early days but Ultragenyx Pharmaceutical Inc. likes its chances to succeed in the rare neuro-genetic disorder Angelman syndrome where Ovid Therapeutics, Inc. notably flamed out in 2020. Ultragenyx unveiled interim Phase I/II data showing safety and indications of clinical activity on 18 July for GTX-102, a candidate it is developing with GeneTx Biotherapeutics LLC, and now the company has exercised an option to acquire its collaborator.
[Sidebar#SC143415]






